Physician profile
Ericsson Trieu
NPI 1144685504
$6,048.20
in general payments reported to CMS, 2019-2025
31 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $787 · 2022: $130 · 2023: $1,734 · 2024: $1,556 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,934 · Consulting Fee: $175 · Education: $21.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,934.48 |
| Consulting Fee | $175.00 |
| Education | $21.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.34 | 2021-2025 | |
| Amgen INC. | $660.17 | 2023-2025 | Evenity, Prolia, Prolia |
| Radius Health, INC. | $482.10 | 2021-2025 | Tymlos |
| Janssen Biotech, INC. | $476.67 | 2021-2025 | Tremfya |
| Ucb, INC. | $457.59 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $374.11 | 2021-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $348.48 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.12 | 2021-2025 | Ofev, Cyltezo, Jascayd |
| Aurinia Pharma U.S., INC. | $313.85 | 2021-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $257.34 | 2023-2025 | Idacio |
| Pfizer INC. | $247.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $246.87 | 2021-2025 | Saphnelo, Evusheld |
| Alexion Pharmaceuticals, INC. | $126.95 | 2023-2025 | Strensiq |
| Genzyme Corporation | $107.01 | 2023-2025 | |
| Alvogen INC | $104.86 | 2023-2025 | Teriparatide |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $101.16 | 2023-2025 | Hyrimoz, Jubbonti |
| Actelion Pharmaceuticals US, INC. | $91.38 | 2023-2024 | Opsumit, Uptravi |
| Organon LLC | $89.41 | 2024-2025 | Hadlima |
| Glaxosmithkline, LLC. | $72.96 | 2021-2023 | Benlysta |
| Cumberland Pharmaceuticals, INC. | $68.21 | 2021-2023 | Reditrex |
| Mallinckrodt Hospital Products INC. | $53.39 | 2025 | Acthar |
| Kiniksa Pharmaceuticals International, Plc | $51.14 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $44.67 | 2023 | Arcalyst |
| Horizon Therapeutics Plc | $43.85 | 2021 | |
| Scilex Pharmaceuticals INC. | $38.39 | 2024-2025 | |
| Genentech USA, INC. | $29.24 | 2021-2024 | Actemra |
| Kyowa Kirin, INC. | $25.61 | 2023 | Crysvita |
| Celltrion USA INC. | $21.73 | 2023 | Yuflyma |
| Tonix Medicines, INC. | $21.14 | 2025 | Tonmya |
| Sobi, INC | $20.09 | 2023 | |
| Hikma Pharmaceuticals USA | $16.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericsson Trieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.